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SUMMARY
We report that knocking down the expression of inositol polyphosphate 4-phosphatase type II (INPP4B) in
human epithelial cells, like knockdown of PTEN, resulted in enhanced Akt activation and anchorage-indepen-
dent growth and enhanced overall motility. In xenograft experiments, overexpression of INPP4B resulted in
reduced tumor growth. INPP4B preferentially hydrolyzes phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2)
with no effect on phosphatidylinositol-3.4.5-triphosphate (PI(3,4,5)P3), suggesting that PI(3,4)P2 and
PI(3,4,5)P3 may cooperate in Akt activation and cell transformation. Dual knockdown of INPP4B and PTEN
resulted in cellular senescence. Finally, we found loss of heterozygosity (LOH) at the INPP4B locus in
amajority of basal-like breast cancers, as well as in a significant fraction of ovarian cancers, which correlated
with lower overall patient survival, suggesting that INPP4B is a tumor suppressor.INTRODUCTION
During the generation and progression of epithelial tumors,
oncogenes and tumor suppressor genes cause multiple cell-
autonomous alterations, resulting in aberrant control of prolifer-
ation, apoptosis, angiogenesis, and cellular life span (Hahn
and Weinberg, 2002). The cyclic regulation of the mammary
gland confers vulnerability to these cancer-promoting pro-
cesses, and imbalances between proliferation and apoptosis
sets the scene for mammary tumorigenesis (Scheid and Wood-
gett, 2001). The phosphinositide 3-kinase (PI3K)-Akt pathway
is deregulated in a wide spectrum of human cancers, and gain
or loss-of-function mutations of several components of
the pathway lead to neoplastic transformation in variousmodel systems (Engelman et al., 2006; Vivanco and Sawyers,
2002).
In vivo activation of PI3K increases the intracellular amounts
of phosphatidylinositol(3,4)bisphosphate (PI(3,4)P2) and phos-
phatidylinositol(3,4,5)trisphosphate (PI(3,4,5)P3). A variety of
signaling proteins, including the Ser/Thr kinases Akt and PDK1,
are able to bind to one or both of these PI3K lipid products
and are thereby localized to the plasma membrane to initiate
cell growth and cell survival pathways. (Plas and Thompson,
2005; Manning and Cantley, 2007).
The termination of signaling downstream of PI3K by degrada-
tion of PI(3,4,5)P3 can be mediated by two different types of phos-
phatases. PTEN dephosphorylates the 3-position of PI(3,4,5)P3
to produce PI(4,5)P2, whereas SHIP family phosphatasesSIGNIFICANCE
Loss-of-function mutations or deletions of PTEN and activating mutations or amplifications of PIK3CA are among the most
common events in solid tumors. Here, we show that the phosphoinositide phosphatase INPP4B plays a role similar to that of
PTEN in suppressing the PI3K/AKT signaling pathway, thereby suppressing tumor growth. We also show that INPP4B is
frequently deleted in a variety of solid tumors, including the majority of basal-like breast cancers. These results suggest
that PI3K pathway inhibitors in current clinical trials may be effective in treating cancers where INPP4B is deleted.Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc. 115
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Loss of PTEN protein expression or function is frequently
observed in human cancers (Vazquez and Sellers, 2000), and
deletion of PTEN in mice results in a variety of tumors (Di Cristo-
fano et al., 1998; Kishimoto et al., 2003), indicating that uncon-
trolled signaling through PI3K contributes to cancer formation
and metastasis. In contrast, loss of genes for SHIP family
members has not been correlated with solid tumor formation;
thus, the role of these phosphatases in regulating PI3K signaling
is complex and controversial. Some studies have indicated that
SHIP family members suppress PI3K signaling (Scheid et al.,
2002; Sharrard and Maitland, 2007; Sleeman et al., 2005),
whereas other studies suggest that the product of SHIP family
members, PI(3,4)P2, is a positive regulator of Akt (Franke et al.,
1997; Frech et al., 1997; Klippel et al., 1997; Scheid et al.,
2002). The PH-domains of Akt and PDK1 bind both PI(3,4)P2
and PI(3,4,5)P3 in vitro, suggesting these lipids may be redundant
in their ability to mediate Akt activation (Cantley, 2002). The
possibility that both PI(3,4,5)P3 and PI(3,4)P2 may be necessary
for optimal growth signaling downstream of PI3K has not been
adequately addressed.
The inositol polyphosphate 4-phosphatase type II (INPP4B)
was initially isolated from rat brain as an enzyme that hydrolyzes
the 4-position phosphate of PI(3,4)P2 and, to a lesser degree,
inositol(3,4)bisphosphate (Ins((3,4)P2) and Ins(3,4,5)P3, in vitro
(Norris et al., 1997; Norris et al., 1995). The ability of INPP4B to
hydrolyze PI(3,4,5)P3 and its effects on phosphoinositides in
intact cells was not investigated; thus, the in vivo function of
INPP4B remains elusive. However, INPP4B expression was
recently shown to be silenced in malignant proerythroblasts.
These cells displayed increased phospho-Akt levels, which
could be reduced by re-expression of INPP4B (Barnache et al.,
Figure 1. AModel Indicating the Roles of PTEN and INPP4B in Regu-
lation of Signaling Downstream of Class I PI3Ks
Upon stimulation of Class 1 PI3Ks, two major phospholipid pools are gener-
ated: PI(3,4,5)P3 and PI(3,4)P2. PTEN hydrolyzes the 3
0-phosphate of
PI(3,4,5)P3 to terminate PI3K signaling. However, SHIP family members hydro-
lyze the 50-phosphate of PI(3,4,5)P3 to generate PI(3,4)P2, which, like
PI(3,4,5)P3, can facilitate PDK1-dependent phosphorylation and activation of
AKT. INPP4B converts PI(3,4)P2 to PI(3)P. Loss of PTEN or loss of INPP4B
results in prolonged activation of Akt and, subsequently, in increased cell
proliferation, cell migration, and invasion.116 Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc.2006). In addition, recent studies described a frequently deleted
region in breast cancer cell lines and basal-like, high-grade
breast tumors, using high-resolution comparative genomic
hybridization analysis (chromosome location 4q31.1-31.21 and
chromosome location 4q31.3-q32.1, respectively), comprising
6 genes, including INPP4B (Naylor et al., 2005; Bergamaschi
et al., 2006; Chin et al., 2007). Johannsdottir et al. (2004) also
found LOH in this region in breast cancers. Furthermore, INPP4B
was identified out of a collection of RNAis to give rise to
anchorage-independent growth in human mammary epithelial
cells (HMEC) (Westbrook et al., 2005).
These observations raise the possibility that INPP4B might be
affecting PI3K signaling in vivo and that it might function as
a tumor suppressor. In this study, we investigate this possibility
with retroviral knockdown of INPP4B in human epithelial cell
systems.
RESULTS
Knockdown of INPP4B Results in
Anchorage-Independent Growth
To investigate the role of INPP4B on cell transformation in the
human mammary epithelial cell line HMEC, retroviral hairpin
constructs (shRNA) were used to knockdown its expression. An
shRNA construct directed against Renilla luciferase (shRNA-
Renilla) was used as negative control for the experiments. Two
shRNA constructs (shRNA-INPP4B-1 and shRNA-INPP4B-2)
were found to effectively reduce expression of INPP4B in several
cell lines, as judged by decreased mRNA levels (Figure 2A). In
MCF-7 cells, where INPP4B protein levels were high enough to
be detected by western blotting, these constructs were shown
to reduce INPP4B protein to the same extent (Figure 2B). Infec-
tion of HMEC cells with either shRNA-INPP4B-1 or shRNA-
INPP4B-2 resulted in anchorage-independent growth compa-
rable to that observed with an shRNA directed against PTEN
(Figures 2C and 2D). Knocking down INPP4B or PTEN also
increased the rate of proliferation of HMEC cells and the effect
of knocking down INPP4B could be reversed by expression of
a knockdown resistant INPP4B, indicating that the shRNA was
acting on target (Figure 2E).
INPP4B Knockdown Results in Increased Migratory and
Invasive Behavior of Human Mammary Epithelial Cells
Migration and invasion are hallmarks of tumor cells with the
potential to metastasize to new locations in the body. To analyze
the migratory behavior of human mammary epithelial cells,
HMEC cells expressing the various shRNA constructs were
grown until confluency, and a scratch wound was introduced
with a pipette tip. Pictures were taken at time points t = 0 hr
and t = 8 hr, as indicated (Figure 3A). Cells expressing shRNA
directed against PTEN and INPP4B closed the wound more
rapidly than did control cells (Figure 3A; quantified in Figure 3B).
The increased rate of wound closure due to INPP4B knockdown
was partially rescued by expressing a wild-type INPP4B
construct that circumvents the knockdown (INPP4BR) but was
not affected by expressing the catalytically inactive mutant of
INPP4B (INPP4B-CD) (Figure 3C; expression of INPP4BR and
INPP4B-CD is presented in Figure S1, which is available with
this article online). The PI3K inhibitor LY294002 also reduced
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pools significantly, consistent with the idea that increased cell
migration was due to elevated PI(3,4)P2 or PI(3,4,5)P3 levels for
INPP4B or PTEN knockdown, respectively (Figure 3D).
We also investigated the effect of knocking down INPP4B on
the ability of MCF-10A cells to intravasate through a Matrigel
layer in a Boyden chamber, revealing the invasive nature of
shRNA knockdown cell pools. As shown in Figure 3E, knocking
down INPP4B had a greater effect on promoting migration
through Matrigel than did knocking down PTEN.
Figure 2. Knockdown of INPP4B Results in Anchorage-Independent
Growth and Increased Cell Proliferation
(A) Semiquantitative RNA levels of stable HMEC shRNA-INPP4B knockdown
colonies grown in anchorage-independent growth assays determined by
RT-PCR. Both shRNA hairpins, INPP4B-1 and INPP4B-2, directed against
INPP4B resulted in approximately 65% knockdown at the RNA level (n = 3).
(B) Knockdown of INPP4B and PTEN in MCF-7 cells. The human mammary
epithelial cancer cell line MCF-7 was infected with shRNA hairpins directed
against Renilla, PTEN, and INPP4B (INPP4B-1 and INPP4B-2). Protein levels
of INPP4B and PTEN in cells expressing the indicated shRNA were determined
by using immunoblotting. Protein loading was shown using antibody directed
against GSK3beta.
(C) Anchorage-independent growth assay of stable HMEC cell pools infected
with retrovirus expressing shRNA directed against Renilla, PTEN, and two
hairpin constructs directed against INPP4B (INPP4B-1 and INPP4B-2).
Results are representative of four independent experiments with similar
results. Scale bar, 1 mm.
(D) Quantification of anchorage-independent growth assay of stable HMEC
shRNA cell pools (***p < 0.001; n = 3).
(E) Proliferation assay of stably infected HMEC shRNA cell pools. Cells
from shRNA-Renilla, shRNA-PTEN, shRNA-INPP4B-1, and shRNA-IN-
PP4B+INPP4BR (rescue cell pool expressing knockdown resistant INPP4B)
were counted on days 2, 3, 4, and 5 in a Coulter counter. Averages of three
independent experiments are represented. All data are shown as mean ± SD.In addition to the enhanced migratory behavior, INPP4B
knockdown cells displayed a spindle-like and fibroblastic
morphology, compared with Renilla or PTEN knockdown
controls (Figure S2A), suggestive of an epithelial-mesenchymal
transdifferentiation (EMT) (Lee et al., 2006). Semiquantitative
RT-PCR of selected epithelial and mesenchymal marker genes
Figure 3. Knockdown of INPP4B Results in Strong Migratory and
Invasive Behavior
(A) Knocking down INPP4B or PTEN with shRNA enhances wound closure
following a scratch of confluent HMEC cells. Cells were photographed at
time points t = 0 hr and t = 8 hr after wound introduction. Samples were
observed under a light microscope. Scale bars, 50 mm.
(B) Quantification of wound closure. Displayed are the percentages of wound
closure at 8 hr after wound introduction determined using NIH Image J (aver-
ages from 3 experiments like those in part A are presented; **p < 0.01 and
***p < 0.001).
(C) Expression of an INPP4B sequence (INPP4BR) that circumvents the knock-
down of endogenous INPP4B reverses enhanced wound closure induced by
INPP4B-1 shRNA. Expression of a catalytically inactive form of INPP4B
(INPP4BR-CD) did not suppress wound closure induced by INPP4B-1 shRNA.
The experiment was analogous to that in part A (averages from three experi-
ments are presented; ***p < 0.001).
(D) The PI3K inhibitor, LY294002 (10 mM), inhibits accelerated wound closure
induced by knocking down INPP4B or PTEN in HMEC. The experiments were
analogous to those presented in part A (averages from 3 experiments are pre-
sented: ***p < 0.001 and **p < 0.01).
(E) Knocking down the expression of PTEN or INPP4B enhances the ability of
MCF-10A cells to cross a Matrigel barrier in a Boyden chamber assay. MCF-
10A cells were stably infected with shRNA directed against Renilla, PTEN,
and INPP4B (INPP4B-1 and INPP4B-2). Cells were seeded in transwell cham-
bers containing Matrigel as a barrier. No stimulus was applied to the bottom
chamber, in order to examine nondirectional invasive behavior in knockdown
cell pools; 24 hr after seeding, invaded cells were fixed, stained, and quantified
(averages from 3 experiments are presented; ***p < 0.001). All data are shown
as mean ± SD.Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc. 117
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Catenin, and a subtle decrease in E-Cadherin RNA levels in
INPP4B knockdown cell pools, compared with Renilla control
cell pools (Figure S2B). Furthermore, we observed a strong
increase in the fibroblast marker fibronectin, compared with
the Renilla knockdown control. These changes were consistent
with a more mesenchymal phenotype. In contrast, RNA levels
of EMT markers in PTEN knockdown cell pools revealed a signif-
icant decrease in N-Cadherin and a strong increase in vimentin
levels, but increased E-Cadherin levels and little fibronectin
expression (Figure S2C).
INPP4B Knockdown in MCF-10A Mammary Epithelial
Cells Results in Distorted Acini Architecture
in Three-Dimensional Culture
Using the MCF-10A three-dimensional culture model of
mammary epithelial cells, we examined how knockdown of
INPP4B influenced the morphogenesis of polarized epithelial
structures. Knockdown of INPP4B or PTEN in MCF-10A cells
resulted in enhanced and dysmorphic growth of acini in three-
dimensional cultures (Figure 4A, left panels). In parallel, cells
were treated with the mTORC1 inhibitor rapamycin, the PI3K
inhibitor LY294002, or with the MEK inhibitor UO126 starting
day 1 of culture (Figure 4A, middle and right panels). Rapamycin
had only a minor effect on dysmorphic growth of INPP4B knock-
Figure 4. Knocking Down INPP4B or PTEN in MCF-10A Cells
Results in Dysmorphic Cell Clusters upon Growth in Three-
Dimensional Culture, and Overexpression of INPP4B
Suppresses Tumor Growth in the SUM149 Xenograft Mouse
Model
(A) Stable MCF-10A shRNA cell pools were grown on a Matrigel layer
under differentiating conditions and observed at day 21 of culture. Left
panels display grown, untreated spheres of Renilla, PTEN, and
INPP4B knockdown cells. The same stable shRNA cell pools were
treated starting day 1 with 1 nM Rapamycin (middle left panels),
10 mM LY294002 (middle right panels), or 10 mM UO126, respectively
(right panels). Representative pictures are shown. The experiment
was repeated three times with similar results. Scale bar, 50 mm.
(B) Nude mice were injected with the human invasive ductal carcinoma
cell line SUM149 expressing Flag-INPP4B (n = 4) or empty Flag control
(n = 4). Mice were sacrificed 4 weeks postinjection, and tumor growth
and size were evaluated. All mice injected with SUM149 cells express-
ing empty Flag vector showed tumor growth (n = 4), whereas mice in-
jected with SUM149 cells expressing Flag-INPP4B showed reduced
tumor growth and size (n = 2).
(C) Quantification of tumor diameter in xenograft experiment. All mice
in the control group (SUM149+Flag Empty) showed tumor growth
(n = 4). Overexpression of Flag-INPP4B in SUM149 resulted in
reduced tumor growth (n = 4; p = 0.011).
(D) Protein levels of INPP4B in SUM149 cells expressing empty Flag
vector or Flag-INPP4B were determined by using immunoblotting.
Protein loading was shown using antibody directed against p85.
down acini in three-dimensional assays and did not have
any impact on PTEN knockdown cell pools. LY294002
and UO126 treatment caused a general growth delay of
acini formation, resulting in smaller spheres than in
untreated cell pools. In INPP4B and PTEN knockdown
cell pools, UO126 treatment only delayed the onset of
architecturally disturbed acini growth, but LY294002
treatment resulted in almost normal appearance of spheres,
comparable to Renilla knockdown controls. These data suggest
that signals downstream of PI3K/Akt are important for the
disturbed architectural growth of INPP4B knockdown spheres.
Overexpression of INPP4B in SUM149 Cells Reduced
Tumor Growth in a Xenograft Mouse Model
The human invasive ductal carcinoma cell line SUM149 was in-
fected with a retroviral vector expressing Flag-INPP4B or Flag-
tag only, and the resultant cells were subcutaneously injected
into nude mice. The SUM149 cells expressing empty Flag-vector
produced much larger tumors than did cells expressing Flag-
INPP4B (Figure 4B, quantified in Figure 4C). The total level of
INPP4B was approximately 2–3-fold higher in the SUM149 cells
expressing Flag-INPP4B, compared with levels in control
SUM149 cells (Figure 4D). These data indicate that overexpres-
sion of INPP4B in the human mammary tumor cell line SUM149
suppresses tumor growth in a xenograft mouse model.
Effect of INPP4B on Cellular Phosphoinositides
Previous studies have indicated that INPP4B hydrolyzes
PI(3,4)P2; however, PI(3,4,5)P3 hydrolysis was not examined,
and the effect of INPP4B on cellular phosphoinositides was not
investigated (Norris et al., 1995). In Figure 5A, we show that
INPP4B prefers PI(3,4)P2 over PI(3,4,5)P3 in in vitro assays. To118 Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc.
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overexpressed the enzyme in 3T3-L6 myoblast cells, a cell line
that produces easily detectable levels of PI(3)P, PI(3,4)P2,
PI(3,5)P2, and PI(3,4,5)P3 (Mandl et al., 2007). The cellular level
of PI(3,4)P2 in INPP4B-expressing cells was reduced signifi-
cantly. In contrast, the levels of the other lipids, including
PI(3,4,5)P3, were not affected (Figure 5B). Although one might
expect an increase in PI(3)P due to hydrolysis of the 4-position
of PI(3,4)P2, PI(3)P is at much higher levels than PI(3,4)P2, and
most of this lipid is probably produced by class III PI3K, rather
than through hydrolysis of PI(3,4)P2. These findings indicate
that the effects of INPP4B knockdown in the mammary epithelial
cell system are due to elevated PI(3,4)P2 levels alone, rather than
elevated PI(3,4,5)P3 levels, as is the case for PTEN knockdown.
Knockdown of Both INPP4B and PTEN Leads to Cellular
Senescence
To address whether INPP4B and PTEN have redundant func-
tions, HMEC cells were subjected to dual knockdown of INPP4B
and PTEN. Unexpectedly, knocking down INPP4B and PTEN
simultaneously resulted in decreased cell proliferation,
compared with Renilla knockdown control (Figure 6A), and re-
sulted in fewer anchorage-independent colonies, compared
with INPP4B or PTEN single knockdown cell pools (Figures 6B
Figure 5. Substrate Specificity of INPP4B
(A) FLAG-tagged INPP4B was immunoprecipitated from 293T cells and was
incubated with either [32P]-PI(3)P, [32P]-PI(3,4)P2, or [
32P]-PI(3,4,5)P3. As
a control, the phosphoinositides were incubated with Flag-immunoprecipitate
from transfected 293T cells expressing an empty Flag-expression construct.
The percentage of hydrolysis of each lipid was determined by chloroform/
methanol/HCL extraction, thin-layer chromatography, and Phosphoimager
analysis. (n = 3; ***p < 0.001).
(B) Overexpression of human INPP4B causes a reduction in cellular PI(3,4)P2
levels in vivo. 3T3-L6 cells were transiently transfected with empty Flag or
Flag-INPP4B constructs and were labeled with [32P]-inorganic phosphate.
Lipids were extracted and deacylated, and the headgroups were separated
by HPLC. The radioactivity in the glyceroyl-phosphoryl-inositol moieties of
each of the D-3 phosphorylated phosphoinositides was then normalized to
the total radioactivity in the more abundant phosphoinositides, PI(4)P and
PI(4,5)P2 (which did not significantly vary between experiments). The bars indi-
cate percentage changes in these ratios in INPP4B transfected cells
compared with control cells. The actual ratios of radioactivity in each lipid to
total radioactivity in PI(4)P plus PI(4,5)P2 in the control 3T3-L6 cells were as
follows: PI(3)P, 3.2%; PI(3,5)P2, 0.035%; PI(3,4)P2, 0.17%; and PI(3,4,5)P3,
0.69% (averages from three experiments are presented; *p < 0.1). Protein
expression of Flag-INPP4B in 3T3-L6 cells was demonstrated by Immunoblot-
ting. Protein loading was shown in using antibody directed against PTEN
(inset). All data are shown as mean ± SD.
Figure 6. Double Knockdown of INPP4B and PTEN in HMEC Cells
Results in Increased Cellular Senescence
(A) Proliferation assay of stably infected HMEC shRNA cell pools including
double knockdown of INPP4B and PTEN. Cells were counted on indicated
days. Results are representative of three independent experiments with similar
results.
(B) Morphology of anchorage-independent growth assays of stable HMEC cell
pools infected with retrovirus expressing shRNA directed against Renilla,
PTEN, INPP4B, and INPP4B + PTEN. Results are representative of three
independent experiments with similar results. Scale bar, 1 mm.
(C) Quantification of anchorage-independent growth assay of stable HMEC
shRNA cell pools (***p < 0.001; n = 3).
(D) SA-beta-Gal activity of stable shRNA HMEC cell pools without or with
knockdown of Trp53 was assessed. The error bars indicate the standard devi-
ation of three replicates (n = 3; *p < 0.1 and ***p < 0.001). Data are shown as
mean ± SD.
(E) Protein levels of INPP4B, PTEN, and Trp53 in cells expressing the indicated
shRNA were determined by using immunoblotting. Protein loading was shown
using antibody directed against p85. All data are shown as mean ± SD.Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc. 119
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knockdown cells were larger than those formed from cells with
single knockdown of INPP4B or PTEN (Figure 6B). These results
indicate that loss of both INPP4B and PTEN results in impaired
cell growth but that rare events (genetic or epigenetic) occur in
the double knockdown cells that allow enhanced growth,
compared with knockdown of either INPP4B or PTEN alone.
Since mutations in K-ras, B-raf, PTEN, and NF-1 have been
shown to trigger cellular senescence in vivo (Chen et al., 2005;
Collado et al., 2005; Braig et al., 2005; Courtois-Cox et al.,
2006; Dankort et al., 2007), we investigated the effect of knock-
ing down PTEN or INPP4B on senescence of HMEC cells. In
Figure 6D, we show that knocking down expression of PTEN
or INPP4B leads to increased cellular senescence, whereas
knocking down both INPP4B and PTEN results in a dramatic
increase in cellular senescence. Ras- or PTEN-induced senes-
cence can be bypassed by inactivating the Rb and transforma-
tion related protein 53 (Trp53) pathways. Cell senescence in
INPP4B knockdown cell pools, as well as in INPP4B and PTEN
dual knockdown cell pools, could be rescued by knocking
down Trp53 using a retroviral hairpin construct (Figure 6D). The
effect of the shRNAs against INPP4B, PTEN, and Trp53 on
protein levels is presented in Figure 6E. Representative pictures
of HMEC knockdown cell pools stained for the senescence
marker SA-beta-Gal are shown in Figure S3.
INPP4B Knockdown Affects the PI3-Kinase/Akt Signal
Transduction Pathway
Time course experiments were performed to compare the
effects of INPP4B knockdown versus PTEN knockdown on Akt
signaling. Knocking down INPP4B or PTEN in HMEC cells had
little effect on basal Akt activation (as judged by phosphorylation
at Thr-308 or Ser-473) but had a significant effect on the magni-
tude and duration of insulin-stimulated Akt activation (Figures 7A
and 7B). This was also reflected in an increase in phosphoryla-
tion of Tuberin and GSK3beta at sites known to be dependent
on AKT (Figure S4). Expression of a form of INPP4B that circum-
vents knockdown (INPP4BR) suppressed AKT activation. Dual
knockdown of INPP4B and PTEN in HMEC cells caused
a more prolonged phosphorylation of AKT at Thr308 than that
caused by knocking down either protein alone (Figure S5).
Loss of Heterozygosity of INPP4B in BRCA1 Mutant
and Basal-like Breast Tumors
To detect potential genomic alterations of inpp4b in breast
cancer, we analyzed a 10K SNP array set of 43 previously pub-
lished breast cancers (Richardson et al., 2006). Comparison of
LOH patterns in the major subtypes of high-grade breast cancer
revealed that allelic loss at 4q31.21 was predominantly seen in
the sporadic triple-negative (basal-like) tumors and in tumors
arising in patients carrying a brca1 germline mutation. Figure 8A
presents frequency (percentage) of allelic loss at chromosome
position 4q31.21 for each tumor group. LOH in region 4q31.21
occurred in 60%, 55.6%, and 5% of BRCA1 mutant, sporadic
basal-like, and high-grade non-basal-like tumors, respectively
(p < 0.001). inpp4b mRNA expression level determined using
two different array probes for inpp4b revealed lower relative
expression (progressively darker shades of blue color) in
BRCA1 mutant (B1) and sporadic basal-like breast tumors,120 Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc.compared with other high-grade breast tumors (Figure 8B). The
triple-negative or basal-like tumor subtype, in which LOH and
decreased expression of inpp4b was observed, is frequently
a tumor subtype noted for increased metastatic potential and
poor patient outcome (Sorlie et al., 2001; Kapp et al., 2006).
Probing a different cohort of breast cancer patient tissues,
comprising mostly subclasses other than BRCA1 mutant and
basal-like with an antibody directed against INPP4B, we found
a significant correlation between loss of INPP4B protein expres-
sion and decreased overall patient survival (Figure 8C; patient
information is summarized in Table S1; examples of scoring
patient tissue for INPP4B expression levels by immunohisto-
chemistry are shown in Figure S6). Breast cancer patient tissues
were also stained for progesterone receptor (PR), estrogen
receptor (ER), and Heregulin2 (Her2)/NEU expression levels in
order to indicate hormone dependence of breast tumor tissue
(Table S1). These data suggest that loss of INPP4B expression
in breast tumor tissues is associated with poor patient outcome.
Figure 7. Knocking Down the Expression of INPP4B Increases the
Duration of AKT Activation in Response to Insulin
(A) Stable HMEC cell pools expressing shRNA vectors directed against Renilla,
PTEN, INPP4B (INPP4B-1), or HMEC cell pools expressing the knockdown-
resistant INPP4B expression construct in the shRNA-INPP4B-1 cell pool
(INPP4B-1 + INPP4BR) were serum-starved and stimulated with 100 nM insulin
for the indicated time periods. Cell lysates were separated by SDS-PAGE, and
phospho-Akt was detected with specific antibodies in western blot analysis.
INPP4B knockdown cell pools display increased and prolonged phospho-
Thr308 and phospho-Ser473 Akt, compared with Renilla control knockdown
cell pools. Expression of a Flag-tagged INPP4B construct harboring two silent
mutations at Ser487 to render it resistant to shRNA knockdown in shRNA-
INPP4B-1 cell pools (INPP4BR) reversed prolonged Akt phosphorylation.
The results are representative of 4 separate experiments.
(B) Quantification of phospho-Thr308 Akt normalized to total Akt levels (n = 4;
*p < 0.1, **p < 0.01, and ***p < 0.001). Quantification of each single time point
was determined using NIH ImageJ (n = 4). Data are shown as mean ± SEM.
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Mutant and Basal-Like Breast Cancers and Ovarian Cancers and
Correlates with Decreased Overall Patient Survival and Lymph
Node Involvement
(A) Frequency of LOH in the 4q31 region of Chromosome 4 from 43 high-grade
human breast tumors is shown. In the data set, five tumors were carrying
germline BRCA1 mutations, 18 additional tumors displayed basal-like
features, and 20 tumors were non-basal-like. The data come from 10K SNP
array and were analyzed using dChip software. LOH of INPP4B, located at
4q31.21, occurred in 60%, 55.6%, and 5% of BRCA1 mutant, basal-like,
and non-basal-like tumors, respectively (p < 0.001).
(B) Differential expression of INPP4B in subtypes of breast cancers analyzed
by gene expression array. Sample subsets are indicated across the top as
follows: BRCA1 germline mutation-associated tumors (B1, pink), sporadic
basal-like tumors (basal-like, red), Luminal predominantly ER positive and
HER2 negative tumors (ER+/HER2-, blue), and HER2 positive tumors
(HER2+, green), and normal breast samples from mammographic reductions
(Normal, yellow). Each column represents an individual sample. Each row
represents the relative expression level measured from two different probes
to INPP4B. Relative expression levels are represented as follows: mean levels
are shown in white, expression levels above mean in progressively darker
shades of red, and expression levels below mean in progressively darker
shades of blue. The relative expression color scale is shown at the bottom.
(C) Percentage survival graph over time (in months) for breast cancer tissue
stained for INPP4B expression (n = 112). Tissues from breast cancer patients
were stained for INPP4B and scored for expression levels (0 = no expression,
1 = low expression, and 2 = high expression). Breast cancer patients with no
expression of INPP4B in tumor tissue showed significantly shorter overall
survival, compared with patients with low and high INPP4B expression in
breast tumor tissue (p = 0.0018).
(D) Percentage survival graph over time (in months) for ovarian cancer tissue
stained for INPP4B expression (n = 50). Tissues from ovarian cancer patients
were stained for INPP4B and scored for protein expression levels (0 = no
expression, 1 = low expression, and 2 = high expression). Ovarian cancer
patients with no expression of INPP4B in tumor tissue showed poor overallLOH of INPP4B Correlates with Decreased Survival
in Ovarian Cancer
LOH at 4q31.1-3, the region that includes inpp4b and other
genes, has previously been observed in esophageal cancers
(Sterian et al., 2006), prompting us to investigate chromosomal
locus 4q31.1-3 in a variety of solid cancers. We found high rates
of copy number deletions at 4q31.1-3 in ovarian cancers (39.8%)
and melanomas (21.6%) (Table S2). Copy number loss of inpp4b
on chromosomal locus 4q31.1-3 was not observed as focal dele-
tion but involved various genes in addition to INPP4B. On the
basis of these findings, we investigated levels of INPP4B expres-
sion in randomly chosen ovarian cancers using IHC and found
that, as in breast cancers, low levels of INPP4B correlated with
decreased patient survival (Figure 8D). Also, we found an inverse
correlation between INPP4B expression levels and lymph node
involvement (Figure 8E; patient information is summarized in
Table S3). Furthermore, copy number analysis of a previously
described ovarian tumor cohort revealed that, out of 118 ovarian
tumors investigated, 37 showed deletion at the inpp4b locus only,
8 tumors showed deletion at the pten locus only, and 10 tumors
showed deletion at both the inpp4b locus and pten locus (n =
118; Figure S7A) (Etemadmoghadam et al., 2009). Since we found
high cellular senescence upon loss of both INPP4B and PTEN,
unless Trp53 was also knocked down, we further investigated
whether tumors with deletion of either lipid phosphatase (INPP4B
or PTEN) or both showed Trp53 mutations. Reanalysis of the
described ovarian cohort showed that most tumors harbored
mutations in trp53, whether or not INPP4B or PTEN was deleted
(Figure S7B), consistent with previous studies indicating high
rates of trp53 mutations in this disease (Krypuy et al., 2007).
DISCUSSION
Here, we present evidence that INPP4B functions as a tumor
suppressor. Knocking down the expression of this enzyme in
HMEC cells results in anchorage-independent growth and
enhanced motility, similar to changes induced in response to
knockdown of the PTEN tumor suppressor gene. Knocking
down INPP4B in the human breast epithelial cell line MCF-10A
resulted in dysmorphic growth of acinar structures in three-
dimensional Matrigel cultures and increased intravasation of Ma-
trigel in a Boyden chamber assay. These results were also similar
to those observed upon knocking down PTEN. Knockdown of
INPP4B and knockdown of PTEN both enhanced and prolonged
AKT activation in HMEC cells in response to insulin, indicating
that these two phosphoinositide phosphatases have similar
effects on signaling downstream of PI3K and that they may
play similar roles as tumor suppressors.
However, there were also some differences in cellular
responses to knocking down INPP4B versus PTEN. Knocking
survival, compared with patients with low or high INPP4B expression
(p < 0.0001).
(E) Ovarian cancer tissues were analyzed for correlation of loss of INPP4B
protein expression and lymph node involvement (LN Met). Lymph node metas-
tases were found significantly more frequently in ovarian cancer tissues, which
lost INPP4B protein expression (p = 0.043). The graph displays percentage of
patients with positive lymph nodes over INPP4B expression levels (0 = no
expression, 1 = low expression, and 2 = high expression).Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc. 121
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structure, compared with control cells or cells in which PTEN
was knocked down. In addition, although the HMEC cells in
which INPP4B was knocked down had enhanced N-cadherin
and fibronectin expression, the HMEC cells in which PTEN was
knocked down showed decreases in N-cadherin and fibronectin
but increases in vimentin and E-cadherin. The MCF-10A cells
with INPP4B knockdown also showed a greater ability to invade
a Matrigel barrier than did cells with PTEN knockdown. The simi-
larities and differences observed between loss of PTEN and loss
of INPP4B can probably be explained by the different substrate
specificities of these two phosphatases. PTEN preferentially
dephosphorylates the D-3 position of PI(3,4,5)P3, whereas
here we show that INPP4B preferentially dephosphorylates the
D-4 position of PI(3,4)P2 both in vitro and in vivo. Although
PI(3,4,5)P3 (produced by Class IA PI3Ks) is strongly implicated
in cell transformation and in activation of AKT, the in vivo function
of PI(3,4)P2 is not yet clear (Figure 1). This lipid can be produced
by both class I and II PI3Ks in vitro using PI(4)P as a substrate. It
can also be produced in vitro by SHIP family phosphatases using
PI(3,4,5)P3 as a substrate. The major pathway for producing
PI(3,4)P2 in vivo is not yet clear and may vary from tissue to
tissue, but we clearly show that the main substrate of INPP4B
is PI(3,4)P2, whereas PI(3,4,5)P3 is not affected. Interestingly,
although some pleckstrin homology (PH) domains, such as those
on BTK and Grp1, bind only to PI(3,4,5)P3, other PH domains,
such as those on AKT and PDK1, can bind to both PI(3,4,5)P3
and PI(3,4)P2. Yet other PH domains, such as TAPP1 bind only
to PI(3,4)P2.
Despite apparently redundant abilities of PI(3,4)P2 and
PI(3,4,5)P3 to bind to both AKT and PDK1 PH domains and to
facilitate PDK1 phosphorylation of AKT in vitro, most in vivo
studies have suggested that PI(3,4,5)P3 is more important than
PI(3,4)P2 for Akt activation. For example, deletion of SHIP1,
a phosphatase that converts PI(3,4,5)P3 to PI(3,4)P2, generally
results in enhanced signaling downstream of PI3K, and SHIP1
appears to be a tumor suppressor in hematopoietic cells (Gilby
et al., 2007; Ong et al., 2007). However, one study suggested
that both PI(3,4,5)P3 and PI(3,4)P2 are needed for full activation
of AKT (Scheid et al., 2002). It is also possible that, although
PI(3,4,5)P3 and PI(3,4)P2 are redundant for activation of AKT
in vivo in some tissues, INPP4B (or related family members)
prevents PI(3,4)P2 from achieving the threshold necessary to
activate Akt. In any event, our results indicate that knocking
down INPP4B results in an increase in sustained AKT activation
and cell transformation, similar to that observed upon knocking
down PTEN.
Knocking down both INPP4B and PTEN in mammary epithelial
cells resulted in cellular senescence. Previous studies had
shown that complete loss of PTEN drives cells into senescence
in vivo (Chen et al., 2005). Our finding that knocking down both
INPP4B and PTEN causes a synergistic increase in senescence,
compared with knockdown of either message alone, is consis-
tent with the idea that superactivation of the PI3K pathway can
result in senescence (Nogueira et al., 2008). Consistent with
previous studies, senescence could be circumvented by knock-
ing down Trp53. These results suggest that, although loss of
function of one allele of INPP4B or PTEN will contribute to tumor
formation, loss of function of both alleles of INPP4B or PTEN (or122 Cancer Cell 16, 115–125, August 4, 2009 ª2009 Elsevier Inc.of both) would be selected against in epithelial tumors. This may
explain why we have not detected point mutations in INPP4B in
basal-like breast cancers (Alexander Miron, personal communi-
cation). Recently, LOH of PTEN was detected in a significant
fraction of basal-like breast cancer, whereas point mutations in
PTEN were not found (Saal et al., 2008). This phenomenon is
presumably due to defects in DNA repair causing chromosomal
rearrangements and microcopy number aberrations. The failure
to see point mutations in the remaining allele is consistent with
the idea that complete loss of PTEN results in senescence unless
Trp53 is mutated.
Finally, our results indicate that decreased expression of
INPP4B correlates with poor outcome in both breast cancer
and ovarian cancer patients. Our results indicate that the PI3K
pathway is likely to play a major role in driving this subset of
cancers. A number of PI3K inhibitors are now in clinical trials,
and loss of INPP4B expression may provide a marker for select-
ing patients who will respond to these drugs.
EXPERIMENTAL PROCEDURES
Cell Culture
HMECs expressing hTERT and SV40 LT (TLM-HMECs) were cultured in
mammary epithelial growth medium (MEGM, Cambrex) (Zhao et al., 2003).
MCF-10A cells were maintained as described elsewhere (Debnath et al.,
2003). 293T and 3T3-L6 cells were grown in DMEM with 10% bovine serum.
SUM149PT cell line was provided by S. Ethier and grown as described
elsewhere (http://www.asterand.com/Asterand/human_tissues/149PT.htm).
Stable cell lines were generated by transduction with the indicated retroviral
supernatants in the presence of 10 mg/ml polybrene, and transduced
cells were selected for resistance with puromycin (2 mg/ml) or neomycine
(250 mg/ml). Anchorage-independent proliferation assays were performed as
described elsewhere (Zhao et al., 2003), except that cells were suspended
in a top layer of 2% low-melting agarose (Seakem) in MEGM. For growth
curves, cells were seeded at a density of 1.03 104 cells per well in 6-well plates
and were cultured in MEGM. Cells were trypsinized and counted at days 0, 1,
2, 3, 4, and 5. Insulin stimulation experiments were performed with 100 nM
after overnight serum starvation. Inhibitors concentrations were as follows:
Wortmannin, 50 nM; LY294002, 10 mM; rapamycin, 1 nM; and UO126, 10 mM.
Immunoblotting
Cells were lysed in lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 mg/ml Leupeptin, and 1 mM DTT). Western
blotting was performed with the following antibodies: aPTEN-HRP (Santa Cruz
7974), aP-Ser473Akt (Cell Signaling 9271), aP-Thr308AKT (Cell Signaling
4056), aINPP4B (Santa Cruz 12318), aGSK3beta (Cell Signaling 9315), ap85
(L. Cantley), aAKT(total) (Santa Cruz 8312), aP-Tuberin(Thr1462) (Cell
Signaling 3611S), aP-p70S6kinase(Thr389) (Cell Signaling 9206S), aTuberin
(Cell Signaling 3612), aP-GSK3alpha/beta(Ser21/9) (Cell Signaling 9331S),
and ap70S6kinase (Cell Signaling 2708).
Retroviral Vectors and Virus Production
The shRNA hairpin-expressing retroviral vector MSCV-U6miR30-PIGdeltaRI,
MSCV-U6miR30-PIGdeltaRI-FF2 (Renilla), and MSCV-U6miR30-PIGdeltaRI-
PTEN were a generous gift from Steven Elledge (Harvard University, Boston,
MA). Specific shRNA-hairpins directed against human INPP4B-1 (RHS1764-
9399376) and INPP4B-2 (RHS1764-9207446) were obtained from OpenBio-
systems. Retroviral vector pLXSN was a kind gift from Christopher Carpenter
(Harvard University, Boston, MA). VSV-pseudotyped retroviruses were
produced as described elsewhere (Ory et al., 1996). Specific hairpin directed
against human p53 was obtained from Addgene plasmid 10672, and specific
hairpin directed against PTEN (hygromycin-resistant) was described by Mandl
et al. (2007). Human INPP4B originated from the Origin cDNA expression
library and was a kind gift of Robin Ketteler (Harvard University, Boston,
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at Ser687 to render it resistant to shRNA-INPP4B-1 knockdown. The catalytic-
dead pLXSN/Flag-INPP4BR (INPP4BR-CD) construct harbors a Cys842Ala
mutation to abolish phosphatase activity as well as two silent mutations at
Ser687 to avoid knockdown.
Semiquantitative RT-PCR
Semiquantitative SYBR RT-PCR was performed at the Harvard-BIDMC core
facility (Victoria Petkova) using the following primers: inpp4b, 50-GCC GAC
CAC ATC ACC ACA G-30 (sense) and 50-TTT CCG CTC ACA CTT TCC G-30
(antisense); beta-actin (control), 50-AAC CTA ACT TGC GCA GAA AAC-30
(sense) and 50-TTT ACA CGA AAG AAC TGC TAT C-30 (antisense); e-cad-
herin1, 50-TGC TCT TGC TGT TTC TTC GG-30 (sense) and 50-TGC CCC ATT
CGT TCA AGT AG-30 (antisense); fibronectin, 50-CTG TTA CTG GTT ACA
GAG TAA-30 (sense) and 50-TAG GTC ACC CTG TAC CTG GAA-30 (antisense);
vimentin, 50-ACC AGG TCC GTG TCC TCG T-30 (sense) and 50-CTG CCC AGG
CTG TAG GTG-30 (antisense); gamma-catenin,: 50-TAC GGC AAC CAG GAG
AGC AAG-30 (sense) and 50-TCT TCA GCA CAC TCT CCA GGC-30 (antisense);
and n-cadherin, 50-GCC CCT CAA GTG TTA CCT CAA-30 (sense) and 50-AGC
CGA GTG ATG GTC CAA TTT-30 (antisense).
Morphogenesis Assays
The 3-D culture of MCF-10A cells was performed as described elsewhere
(Debnath et al., 2003). Inhibitor concentrations were as follows: rapamycin
(1 mM stock), 100 mg/ml; and UO126, 10 mM. The assay media DMEM/F12
(supplemented with 3% donor horse serum, 5 ng/ml EGF, 10 mg/ml insulin,
100 ng/ml cholera toxin, 0.5 mg/ml hydrocortisone, and 2% Matrigel) was
replaced with media starting on day 1 and was re-fed every 4 days thereafter.
Where indicated, UO126, rapamycin, or LY294002 was added to cultures at
the reported dose on day 1 of 3-D culture and replaced every 4 days thereafter.
Acini formation was documented with phase contrast pictures.
Matrigel Invasion Assays
Invasion assays were performed using Transwell chambers (Corning) with 8 mm
pore membranes coated with Matrigel. Cells were seeded at a density of 1 3
104 cells/well in triplicate and were allowed to invade through the Matrigel for
24 hr. Growth medium was applied to both sides. Cells that had invaded to
the lower surface of the membrane were fixed and stained with TolueneO blue.
SA-Beta-Gal Activity Assay
SA-beta-Gal staining was performed as described elsewhere (Dimri et al.,
1995), and percentages were assessed by counting at least 300 cells. Cell
pools were infected with shRNA-Trp53 and were analyzed 3 days later. Cells
were stained for 8 hr before evaluation.
In Vitro Phosphatase Assays and In Vivo Analysis
of Phosphoinositides
[32P]-PI(3)P, [32P]-PI(3,4)P2, and [
32P]-PI(3,4,5)P3 were synthesized by incu-
bating PI, PI(4)P, and PI(4,5)P2 with class Ia PI3K (immunoprecipitated from
293T cells) and g-[32P]-ATP (Whitman et al., 1987). Each of the radiolabeled
lipids was incubated for 3 hr at 30C with either INPP4B (Flag-immunoprecip-
itate from 293T cells expressing Flag-INPP4B) or with a control Flag-immuno-
precipitate. The lipids were extracted in chloroform/HCl and separated by thin
layer chromatography (TLC). The substrates and products from each phos-
phatase assay were quantified by Phosphoimager and the percentage of
hydrolysis was calculated. Quantitative high-performance liquid chromatog-
raphy (HPLC) analysis of deacetylated phosphoinositides from [32P]-inorganic
phosphate-labeled L6 cells was performed as described elsewhere (Auger
et al., 1989). Counts for each single phosphatidylinositol lipid were normalized
to combined counts of the major phosphoinositides, PI(4)P, and PI(4,5)P2.
Immunohistochemistry
The study cohort comprised breast and ovarian tumors consecutively ascer-
tained at the Memorial Sloan-Kettering Cancer Center (MSKCC). All biopsy
specimens were evaluated at MSKCC, and the histologic diagnosis was based
on established standard criteria. Use of tissues was approved by Institutional
Review Board (IRB) waivers and the Human Biospecimen Utilization
Committee (HBUC). TMAs were stained with INPP4B (goat polyclonal,sc-12318, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, at 1:150 dilution)
and PTEN (mouse monoclonal, clone 6H2.1, Cascade Bioscience Inc,
Winchester, MA, at 1:75 dilution). Antibodies were applied after pretreatment
with 10 mM citrate buffer (pH 6.0) and microwave. Secondary antibody bioti-
nylated anti-goat made in rabbit (1:500) and ABC (avidin-biotin conjugate) Elite
Vectastain (1:25) (Vector Lab, Burlingame, CA) were applied. PTEN was
stained and scored as published elsewhere (Song et al., 2008).
Copy Number Deletion Analysis
Copy number loss of INPP4B in tumor tissues was analyzed as described by
Lin et al. (2008). Analysis of ovarian tumor tissue for loss of INPP4B and
PTEN expression was performed as described elsewhere (Etemadmoghadam
et al., 2009). The study population consisted of 118 patients diagnosed with
epithelial ovarian, primary peritoneal, or fallopian tube cancer. The Australian
Ovarian Cancer Study (AOCS) was performed by the Westmead Hospital
(n = 73, Sidney, Australia). Other samples originated from Haukeland Univer-
sity Hospital of Bergen (Bergen, Norway), and Jikei University (Tokyo, Japan).
This project had institutional ethics review board approval at all participating
centers. The AOCS samples subset was further analyzed for Trp53 mutation,
as described elsewhere (Krypuy et al., 2007).
Xenograft Experiments
SUM149PT cells infected with pLXSN-Flag, empty, or pLXSN-Flag-INPP4B
were selected for 2 weeks. Male nude mice were injected with 1 3 106 cells
resuspended in 100 ml of Matrigel at the right flank. Tumors were grown over
a time period of 4 weeks, and mice subsequently were sacrificed. Tumor
occurrence and size were evaluated. All animal procedures followed protocols
approved by the Animal Care and Use Committee (IACUC), Beth Israel
Deaconess Medical Center at Harvard Medical School.
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